Novartis pays $7.8 billion for Abogen mRNA asset
Novartis agreed to pay up to $7.8 billion for global rights to an early-stage mRNA therapy from China's Abogen Biosciences, the latest and largest in
Every Fin-node story mentioning AstraZeneca — 7 stories, newest first.
Novartis agreed to pay up to $7.8 billion for global rights to an early-stage mRNA therapy from China's Abogen Biosciences, the latest and largest in
AstraZeneca agreed to invest $2 billion in Summit Therapeutics on Monday, sending the biotech’s shares up as much as 19 percent in after-hours trading
AstraZeneca shares fell roughly 9 percent early this month after the Financial Times reported the U.K. drugmaker was close to a merger with Bristol My
AstraZeneca shares fell roughly 9 percent after the Financial Times reported the U.K. drugmaker was close to merging with Bristol Myers Squibb in a de
Novo Nordisk shares fell 10% last week after its experimental cardiovascular drug ziltivekimab failed to prevent heart attacks, strokes or cardiovascu
The Dow Jones Industrial Average closed at a record high Monday as optimism around U.S.-Iran talks lifted sentiment, though the session's sector rotat
AstraZeneca shares dropped 6.1 per cent to 11,860p in early London trading on Monday after the Financial Times reported the UK drugmaker has held talk